Obicetrapib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Obicetrapib
- Molecular weight
- 722.61
- Structure (SMILES)
- CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2ncc(OCCCC(=O)O)cn2)C[C@H]1CC
- amg 899
- AMG-899
- casa
- CASA
- dez 001
- DEZ-001
- obicetrapib
- Obicetrapib
- obicetrapib [INN]
- OBICETRAPIB [USAN]
- Obicetrapib [WHO-DD]
- Obicetrapib 10 mg
- Obicetrapib 10mg
- Obicetrapib 5mg
- obicetrapib inn
- obicetrapib usan
- obicetrapib who dd
- ta 8995
- Ta-8995
- TA-8995
- ATC classification codes
- C10A
- CAS registry numbers
- 866399-87-3
- ChEMBL ID
- CHEMBL3785197
- InChIKey
- NRWORBQAOQVYBJ-GJZUVCINSA-N
- PubChem compound IDs
- 11498596
- FDA ingredient codes (UNII)
- 8O74K609HN
- Status
- opinion
- Status date
- 23 Jul 2026
- Approved indications
- Treatment of primary hypercholesterolaemia or mixed dyslipidaemia.
- Product number
- EMEA/H/C/006516
- Authorisation holder
- A. Menarini International Licensing S.A.
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Dyslipidemias
- Hypercholesterolemia
European medicines record
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- obicetrapib
- Type
- Synthetic organic
- Drug name stem
- -cetrapib
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- cholesteryl ester transfer protein
- Gene symbol
- CETP
- Protein identifier
- P11597
- Mechanism
- Cholesteryl ester transfer protein inhibitor
- Action type
- Inhibitor
- Target
- Cholesteryl ester transfer protein
- Protein identifier
- P11597
Open Targets mechanisms
- Mechanism
- Cholesteryl ester transfer protein inhibitor
- Action type
- Inhibitor
- Target
- Cholesteryl ester transfer protein
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Atherosclerosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003914
- Subject identifier
- D050197
- Condition
- Dyslipidemias
- Highest recorded phase
- 1
- Condition identifier
- HP:0003119
- Subject identifier
- D050171
- Condition
- Alzheimer Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition
- Lipid Metabolism Disorders
- Highest recorded phase
- 2
- Condition identifier
- Orphanet:309005
- Subject identifier
- D052439
- Condition identifier
- EFO_0000195
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000319
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003914
- Highest recorded phase
- 3
- Condition identifier
- GO_0006629
- Highest recorded phase
- 1
- Condition identifier
- HP_0003119
- Condition identifier
- HP_0003124
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001336
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002525
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005311
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005439
- Highest recorded phase
- 3
- Condition identifier
- Orphanet_309005
- Highest recorded phase
- 2
- NCT01878474
- NCT01879020
- NCT01970215
- NCT02241759
- NCT02408055
- NCT02523391
- NCT05161715
- NCT05202509
- NCT06048302
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 1
- Polar surface area
- 105.09
- Calculated partition coefficient (ALogP)
- 8.67
- Calculated partition coefficient (XLogP)
- 7.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 11
- Heavy atoms
- 50
- Molecular formula
- C32H31F9N4O5
- Monoisotopic mass
- 722.21507356
- Natural product
- No
- Recorded assays
- 3
- Active assays
- 0
Related records
Trials (26)
- A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
- A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
- A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin
- A Preliminary Drug Drug Interaction Study With TA-8995
- A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)
- A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects
- A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
- ADME Study in Healthy Male Subjects With TA-8995
- Bioequivalence Study of Capsule and Tablet Formulations of TA-8995
- Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
- Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
- Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
- Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
- Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects
- Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects
- Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
- Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
- Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
- PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
- Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
In development for (6)
- Alzheimer disease Phase 2
- Atherosclerosis Phase 3
- Cardiovascular disorder Phase 2
- Familial hyperlipidemia Phase 2
- Inherited lipid metabolism disorder Phase 2
- Liver disorder Phase 1
Targets (1)
- CETP Cholesteryl ester transfer protein inhibitor